CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Home
Companies
CROSSJECT

BRIEF

published on 08/22/2024 at 07:35, 2 months 30 days ago

Crossject to Participate in HC Wainwright’s 26th Annual Global Investment Conference

Investment Conference Crossject ZENEO® HC Wainwright
PRESS RELEASE

published on 08/22/2024 at 07:30, 2 months 30 days ago

Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
Crossject to present at H.C. Wainwright 26th Annual Global Investment Conference on September 9th-11th, 2024, showcasing their needle-free auto-injector ZENEO®

H.C. Wainwright Crossject Needle-free Auto-injector ZENEO® Global Investment Conference
BRIEF

published on 07/18/2024 at 07:35, 4 months 3 days ago

Crossject Achieves Key ZEPIZURE® Manufacturing Milestone

Crossject ZEPIZURE® Manufacturing Milestone FDA EUA ZENEO®
PRESS RELEASE

published on 07/18/2024 at 07:30, 4 months 3 days ago

Crossject achieves key ZEPIZURE® manufacturing milestone
Crossject achieves key ZEPIZURE manufacturing milestone with successful completion of new registration batch at Eurofins' qualified facility, supporting EUA timelines

Emergency Use Authorization Crossject ZEPIZURE Eurofins Manufacturing Milestone
BRIEF

published on 06/26/2024 at 07:35, 4 months 25 days ago

Crossject highlights the potential of ZEPIZURE® following RAMPART and bioequivalence studies

Crossject ZEPIZURE® Midazolam RAMPART Study Epileptic Seizures
PRESS RELEASE

published on 06/26/2024 at 07:30, 4 months 25 days ago

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
Crossject provides insights on ZEPIZURE® potential in light of RAMPART and its bioequivalence study. IM midazolam favored over IV lorazepam for emergency epilepsy management

Crossject ZEPIZURE RAMPART Study Bioequivalence Study Emergency Epilepsy Management
BRIEF

published on 06/18/2024 at 12:35, 5 months 2 days ago

Crossject: Information relating to the total number of voting rights and shares making up the share capital

Share Capital Voting Rights AMF Crossject Specialized Pharmacy
BRIEF

published on 06/13/2024 at 09:41, 5 months 8 days ago

Crossject: Information on the number of voting rights and shares

Share Capital Voting Rights Actions 2024 Crossject
BRIEF

published on 06/12/2024 at 07:35, 5 months 9 days ago

Crossject Appoints Dan Chiche, MD as North America Chief Medical Officer

Crossject ZEPIZURE® Dan Chiche Medical Director
PRESS RELEASE

published on 06/12/2024 at 07:30, 5 months 9 days ago

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America, strengthening leadership team and expanding presence in U.S. Supports ZEPIZURE® regulatory milestones targeting in 2025

North America Chief Medical Officer Crossject ZEPIZURE Dan Chiche

Accesswire

Published on 11/21/2024 at 10:03, 34 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 37 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 37 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 2 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 12 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 32 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 35 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 37 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 37 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 36 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 39 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 17 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 52 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 52 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE